H.C. Wainwright lowered the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $26 from $30 and keeps a Buy rating on the shares. The firm cites the Q3 results and completed equity financing for the target drop.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLTX:
- MoonLake Immunotherapeutics Reports Q3 2025 Financial Results
- MoonLake Immunotherapeutics price target raised to $30 from $25 at Oppenheimer
- MoonLake Immunotherapeutics price target raised to $8 from $7 at Goldman Sachs
- MoonLake Immunotherapeutics Announces $75M Share Offering
- MoonLake Immunotherapeutics’ SLK Program: Buy Rating Backed by Promising Trial Results and Upcoming Catalysts